Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | May 24, 2017 | May 25, 2017 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director · CHAIRMAN & CEO | September 01, 2026 | September 03, 2026 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 08, 2017 | September 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date May 24, 2017 · Filed May 25, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2027-05-24 | Direct | 30,000 |
Reported balance
After 2017-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-24 · Grant · Acquired 30,000 · Balance 30,000 F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2: Vests 1/12th per month over twelve months beginning June 24, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
F2: Vests 1/12th per month over twelve months beginning June 24, 2017.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 86,165 |
Reported balance
After 2026-09-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-01 · Exercise / conversion · Acquired 9,991 · Balance 86,165 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,646 |
Reported balance
After 2026-09-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-01 · Exercise / conversion · Acquired 6,481 · Balance 92,646 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 98,883 |
Reported balance
After 2026-09-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Acquired 6,237 · Balance 98,883 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 107,492 |
Reported balance
After 2026-09-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-01 · Exercise / conversion · Acquired 8,609 · Balance 107,492 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,348 |
Reported balance
After 2026-09-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-01 · Tax withholding · Disposed 15,144 · Balance 92,348 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 30,050 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Grant · Acquired 30,050 · Balance 30,050 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 25,826 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 8,609 · Balance 25,826 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 12,475 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 6,237 · Balance 12,475 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 6,481 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Exercise / conversion · Disposed 6,481 · Balance 6,481 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Exercise / conversion · Disposed 9,991 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 120,150 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Grant · Acquired 120,150 · Balance 120,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 | 109,795 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 109,795 |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 | 51,794 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 51,794 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Syros Pharmaceuticals, Inc.
Report date June 08, 2017 · Filed September 22, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2027-06-07 | Direct | 11,000 |
Reported balance
After 2017-06-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-06-08 · Grant · Acquired 11,000 · Balance 11,000 F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person. F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date.
F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 4,924 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · derivative · entry 11 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,272 Underlying: Class A Common Shares · 4,924 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 4,528 | $23.00 | $104,144.00 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · nonDerivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 108,042 F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $23.00 to $23.02. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 4,924 | $23.00 | $113,252.00 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $23.00 to $23.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 00:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 4,924 | $1.59 | $7,829.16 |
DisclosureSEC source: 0001179110-21-001553 · edgar.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on September 3, 2020. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 150,700 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001179110-20-010450 · edgar.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,196 Underlying: Class A Common Shares · 150,700 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 99,330 | $21.02 | $2,087,916.60 |
DisclosureSEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 112,570 F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.00 to $21.08. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 150,700 | $21.02 | $3,167,714.00 |
DisclosureSEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.00 to $21.08. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 12, 2020 Filed Oct 14, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 150,700 | $1.59 | $239,613.00 |
DisclosureSEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person. Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 872 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001179110-20-010450 · edgar.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,896 Underlying: Class A Common Shares · 872 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 670 | $21.00 | $14,070.00 |
DisclosureSEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 211,900 F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person. Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 872 | $21.00 | $18,312.00 |
DisclosureSEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.00 to $21.01. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 21:22 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Shares | 872 | $1.59 | $1,386.48 |
DisclosureSEC source: 0001179110-20-010450 · edgar.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 180,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001179110-20-009723 · edgar.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Class A Common Shares · 180,000 shares Expires 2030-09-09 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 21:23 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 180,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001179110-20-003836 · edgar.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Class A Common Shares · 180,000 shares Expires 2030-03-12 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 21:33 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Shares | 33,115 | $20.00 | $662,300.00 |
DisclosureSEC source: 0001179110-20-003417 · edgar.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 212,570 F1 · kind: The sale of Class A Common Shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 6, 2019. Read SEC document |
| September 17, 2019 Filed Sep 19, 2019 20:17 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 190,000 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001179110-19-010488 · edgar.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Class A Common Shares · 190,000 shares Expires 2029-09-16 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019. Read SEC document |
| August 07, 2019 Filed Feb 13, 2020 22:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass A Common Shares | 245,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001565 · edgar.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 245,685 F1 · shares: The Reporting Person transferred all Class A Common Shares and all Class B Common Shares held by the Reporting Person to a family trust, of which the Reporting Person is trustee, on August 7, 2019 and July 31, 2019, respectively. The Reporting Person is the sole beneficiary of the trust. Read SEC document |
| August 07, 2019 Filed Feb 13, 2020 22:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass A Common Shares | 245,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001565 · edgar.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The Reporting Person transferred all Class A Common Shares and all Class B Common Shares held by the Reporting Person to a family trust, of which the Reporting Person is trustee, on August 7, 2019 and July 31, 2019, respectively. The Reporting Person is the sole beneficiary of the trust. Read SEC document |
| July 31, 2019 Filed Feb 13, 2020 22:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass B Common Shares · Derivative | 1,526,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001565 · edgar.xml · derivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 Disclosed balance after: 1,526,160 Underlying: Class A Common Shares · 1,526,160 shares Expires not disclosed F3 · derivative.exercise_price: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. F1 · shares: The Reporting Person transferred all Class A Common Shares and all Class B Common Shares held by the Reporting Person to a family trust, of which the Reporting Person is trustee, on August 7, 2019 and July 31, 2019, respectively. The Reporting Person is the sole beneficiary of the trust. F3 · derivative.exercise_date: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. F4 · derivative.exercise_date: In accordance with certain contractual arrangements entered into between the Reporting Person and the Issuer, the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 is not entitled to convert the Class B Common Shares into Class A Common Shares, if immediately following such conversion, the Reporting Person would beneficially own more than 4.99% of the Issuer's issued and outstanding Class A Common Shares, unless the Reporting Person provides the Issuer with 61-days' prior written notice of such conversion. F3 · derivative.expiration_date: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. F4 · balance_after: In accordance with certain contractual arrangements entered into between the Reporting Person and the Issuer, the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 is not entitled to convert the Class B Common Shares into Class A Common Shares, if immediately following such conversion, the Reporting Person would beneficially own more than 4.99% of the Issuer's issued and outstanding Class A Common Shares, unless the Reporting Person provides the Issuer with 61-days' prior written notice of such conversion. Read SEC document |
| July 31, 2019 Filed Feb 13, 2020 22:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass B Common Shares · Derivative | 1,526,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001565 · edgar.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 1,526,160 shares Expires not disclosed F3 · derivative.exercise_price: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. F1 · shares: The Reporting Person transferred all Class A Common Shares and all Class B Common Shares held by the Reporting Person to a family trust, of which the Reporting Person is trustee, on August 7, 2019 and July 31, 2019, respectively. The Reporting Person is the sole beneficiary of the trust. F3 · derivative.exercise_date: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. F4 · derivative.exercise_date: In accordance with certain contractual arrangements entered into between the Reporting Person and the Issuer, the Anglia 2013 Revocable Trust, u/d/t August 15, 2013 is not entitled to convert the Class B Common Shares into Class A Common Shares, if immediately following such conversion, the Reporting Person would beneficially own more than 4.99% of the Issuer's issued and outstanding Class A Common Shares, unless the Reporting Person provides the Issuer with 61-days' prior written notice of such conversion. F3 · derivative.expiration_date: Each Class B Common Share is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 23:29 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 187,000 | $0.00 Strike: $17.92 | $0.00 |
DisclosureSEC source: 0001104659-19-013174 · a4.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,000 Underlying: Class A Common Shares · 187,000 shares Expires 2029-03-03 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 4, 2019. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 12:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 125,000 | $0.00 Strike: $30.93 | $0.00 |
DisclosureSEC source: 0001104659-18-058111 · a4.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Class A Common Shares · 125,000 shares Expires 2028-09-19 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter. The vesting commencement date is September 20, 2018. Read SEC document |
| May 29, 2018 Filed May 29, 2018 23:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionClass B Common Shares · Derivative | 428,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-036488 · a4.xml · derivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,526,160 Underlying: Class A Common Shares · 428,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. F4 · derivative.exercise_date: Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. F4 · derivative.expiration_date: Each share of Class B Common Shares is convertible at any time at the election of the holder, subject to certain contractual arrangements entered into between the Reporting Person and the Issuer, into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party. Read SEC document |
| May 29, 2018 Filed May 29, 2018 23:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionSeries C Preferred Shares · Derivative | 63,922 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-036488 · a4.xml · derivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 63,922 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. Read SEC document |
| May 29, 2018 Filed May 29, 2018 23:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionSeries B Preferred Shares · Derivative | 71,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-036488 · a4.xml · derivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Shares · 71,967 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. Read SEC document |
| May 29, 2018 Filed May 29, 2018 23:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionSeries A Preferred Shares · Derivative | 428,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-036488 · a4.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Shares · 428,203 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis. F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis. F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis. Read SEC document |
| May 29, 2018 Filed May 29, 2018 23:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | ConversionClass A Common Shares | 135,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-036488 · a4.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2018 Filed May 29, 2018 23:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | PurchaseSeries C Preferred Shares · Derivative | 63,922 | $15.64 | $999,982.98 |
DisclosureSEC source: 0001104659-18-036488 · a4.xml · derivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,922 Underlying: Class A Common Shares · 63,922 shares Expires not disclosed F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F2 · shares: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018. F2 · price: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis. F2 · derivative.underlying_shares: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018. F2 · balance_after: Reflects the 1-for-2.73235 share consolidation effected May 11, 2018. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:03 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001179110-17-008898 · edgar.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 08, 2017 Filed Sep 22, 2017 21:19 UTC Amendment | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $14.62 | $0.00 |
DisclosureSEC source: 0001179110-17-012629 · edgar.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-07 F2 · derivative.exercise_price: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person. F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| May 24, 2017 Filed May 25, 2017 15:57 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001127602-17-019340 · form4.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-05-24 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning June 24, 2017. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 10:57 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001104659-16-145305 · a4.xml · derivative · entry 1 Patel Sanj K · CIK 0001532218 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2026-09-14 F1 · derivative.exercise_date: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments of 2.77% of the shares underlying the award until the third anniversary of the date of the award, subject to Mr. Patel's continued service as a director through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.